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Introduction
 It is estimated by American Cancer Society that 4,490 
women will be diagnosed with and 950 women will die 
of cancer of the vulva in 2012 (Howlader et al., 2012).
The median age at diagnosis for cancer of the vulva is 68 
years of age and median age at death for cancer of the 
vulva is 79 years of age (Howlader et al., 2012). Treatment 
for early stage vulvar cancer consists of radical excision 
of the tumor with ipsilateral or bilateral inguinofemoral 
lymphadenectomy. Most of vulvar cancer recurrences 
occur in inguinal region and very rarely in the primary 
site of tumor excision (Magrina et al., 1979; Kelley et 
al., 1992; Sidor et al., 2006; Hampl et al., 2009). Several 
studies have described inguinal lymph node recurrences 
in up to 2.4% of cases (Hacker et al., 1983; Bell et al., 
2000; Rodolakis et al., 2000; Ate van der Zee et al., 2008). 
Groin lymph-node metastases have been discovered as 
a most signifficant prognostic factors for vulvar cancer 
recurrence with a 5-year survival of 70-93% in patients 
with negative inguinofemoral lymph-nodes compared to 
25-41% in patients with lymph-node metastases (Gadducci 
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Abstract
 Objective: This observational study was to identify risk factors for vulvar cancer recurrence. Materials and 
Methods: In the study 107 patients with primary vulvar cancer were analyzed. Surgical treatment consisted 
of radical excision of the primary tumor in combination with unilateral or bilateral superficial and deep 
inguinofemoral lymphadenectomy through separate incisions. Patients with deeper tumor invasion >1 mm or 
wider than 2 cm and/or groin lymphnode metastases were referred for adjuvant radiotherapy. Those with large 
privary vulvar tumors received neoadjuvant radiotherapy of 30Gy followed by surgical treatment and adjuvant 
radiotherapy. Results: Most of patients had only primary radiotherapy to the vulva and inguinal lymph nodes 
and only 34.5% of patients were eligible for surgical treatment. In 5 year follow-up period 25.2% (27) patients 
were alive without the disease, 15.0% (16) were alive with the disease and 59.8% (64) were dead. 60.7% (65) 
patients experienced local recurrence and 2.8% (3) patients had distant metastases. Median survival for patients 
without recurrent disease was 38.9±3.2 months and 36.0±2.6 months with no statistically significant difference. 
Patients with early stage vulvar cancer had longer mean survival rates-for stage I 53.1±3.4 months, 38.4±4.4 
months for stage II and 33.4±2.6 and 15.6±5.2 months for patients with stage III and stage IV vulvar cancer, 
respectively. The only signifficant prognostic factor predicting vulvar cancer recurrence was involvement of the 
midline. Conclusions: Patients having midline involvement of vulvar cancer has lower recurrence risk, probably 
because of receiving more aggressive treatment. There is a tendency for lower vulvar cancer recurrence risk for 
patients over 70 years of age and patients who are receiving radiotherapy as an only treatment without surgery, 
but tendency for higher risk of recurrence in patients with multifocal vulvar cancer. 
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 Objective of this observational study was to identify 
risk factors for vulvar cancer recurrence. 
Materials and Methods
 In the study 107 patients with primary vulvar cancer 
were analyzed. Surgical treatment consisted of radical 
excision of the primary tumor in combination with 
unilateral or bilateral superficial and deep inguinofemoral 
lymphadenectomy through separate incisions. A unilateral 
tumor was defined as a lesion that does not cross the 
midline, with the medial margin of the tumor more than 
1 cm from the midline structures. The primary tumor 
was excised with a margin of at least 1 cm of normal 
skin. Unilateral excision was performed for tumors less 
than 2 cm in the diameter and with a deper invasion 
less than 1mm, unless involvement of labia minora and 
positive ipsilateral lymphnodes were detected. Patients 
with deeper tumor invasion >1 mm or wider than 2 cm 
and/or groin lymphnode metastases were referred for 
adjuvant radiotherapy. Patients with large privary vulvar 
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tumors received neoadjuvant radiotherapy of 30Gy with 
a following surgical treatment and adjuvant radiotherapy. 
To evaluate risk factors for vulvar cancer recurrence 
age, FIGO stage, tumor morphology, unilocularity or 
multilocularity, involvement of middline, involvement of 
lymphnodes, extent of surgery, radiotherapy, recurrences, 
distant metastases and 5 year survival rates were assessed. 
All analyses were performed using SPSS software, 
version 20.0 (SPSS Inc, Chicago, IL). Differences in the 
distributions of patient characteristics were analyzed with 
the t test. Overall survival analysis was done using Kaplan-
Meier test. Cox proportional hazard ratio was assessed 
to estimate risk factors for vulvar cancer recurrences. 
Differences associated with a p<0.05 were considered 
significant. 
Results 
 All patients had squamous cell carcinoma. Most of 
them had stage III cancer with unilocular primary leasions 
involving midline and having metastases in the ipsilateral, 
contralateral or bilateral inguinal lymphnodes (Table 1).
Most of patients had only primary radiotherapy to the 
vulva and inguinal lymphnodes and only 34.5% of patients 
were eligible for surgical treatment. In 5 year follow-
up period 25.2% (27) patients were alive without the 
disease, 15.0% (16) were alive with the disease and 59.8% 
(64) were dead. 60.7% (65) patients experienced local 
recurrences and 2.8% (3) patients had distant metastases. 
Median survival for patients without recurrent disease was 
38.9±3.2 months and 36.0±2.6 months for patiens with 
local recurrences and there was no statistically signifficant 





































































































Table 1. Patient Characteristics
Mean age, years (range) 72.5 (37-96)
Tumor locularity, % (n) Unilocular 91.6 % (98)
 Multilocular 8.4 % (9)
Involvement of midline, % (n) Involed 50.5 % (54)
 Not involved 49.5 % (53)
Metastatic lymphnodes, % (n) Ipsilateral 29.0 % (31)
 Bilateral 23.3 % (25)
 Contralateral 2.8 % (3)
 No metastases 44.9 % (48)
FIGO stage, % (n) Stage I 17.8 % (19)
 Stage II 19.6 % (21)
 Stage III 58.9 % (63)
 Stage IV 3.7 % (4)
Table 3. Risk Factors Predicting Vulvar Cancer 
Recurrence
Risk factors HR (95% CI) p
Age, > 70 years 0.61 (0.36-1.05) 0.07
Multilocular leasion vs. Unilocular leasion 1.91 (0.91-4.01) 0.08
Involvement of midline vs. lateral leasion 0.46 (0.28-0.76) 0.02
Lymphnode metastases vs. no metastases 0.83 (0.51-1.36) 0.46
Inguinal lymphadenectomy 0.75 (0.40-1.40) 0.36
Preoparative and postoperative radiotherapy1.66 (0.98-2.81) 0.06
vs. only postoperative radiotherapy
Late stage (FIGO III and IV) vs. early  0.67 (0.40-1.10) 0.12
stage (FIGO I and II) cancer
Figure 1. 5-Year Overall Survival of Patients with 
Vulvar Cancer Recurrence
without local vulvar cancer recurrence (Figure 1). 
 Patients with early stage vulvar cancer had longer 
mean survival rates-for stage I 53.1±3.4 months, 
38.4±4.4 months for stage II and 33.4±2.6 and 15.6±5.2 
months for patients with stage III and stage IV vulvar 
cancer, respectively (Figure 2). The only signifficant 
prognostic factors predicting vulvar cancer recurrence 
was involvement of midline (Table 3).
Discussion
Results from the studies regarding prognostic factors 
for progno tic factors in vulvar cancer are contraversial 
and can be explaine  by small sample size included 
in the retsopective studies and heterogenous treatment 
approaches (Iversen et al., 1980; Burger et al., 1995; 
Gonzalez et al., 2005). Potential risk factors for vulvar 
rancer recurrences include stage, tumour size, depth 
of invasion, tumor free margin, lymphovascular space 
invasion, age and nodal involvement. Althought the 
importance of these risk factors is inconclusive and varies 
across the studies (Andreasson et al., 1985; Podratz et al., 
1983; Hefler et al., 1999; Chan et al., 2007).
Table 2. Treatment Characteristics
  % (n)
Surgical treatment only Radical vulvectomy 33.6 % (36)
 Radical excision 0.9 % (1)
Inguinal lymphadenectomy  
 Bilateral 8.5 % (9)
 Unilateral 6.5 % (7)
 No lymphadenectomy 85.0 % (91)
Radiotherapy Radiotherapy only 64.5 % (69)
 As adjuvant treatment 31.8 % (34)
 No radiotherapy 3.7 % (4)
Figure 2. 5-Year Overall Survival of Patients with 
Vulvar Cancer by Stage
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In this study, 107 patients with primary vulvar 
carcinoma were treated either with primary radical surgery 
following adjuvant radiotherapy or only radiotherapy in 
patients who were not appropriate for surgical treatment 
and were evaluated for risk factors of vulvar cancer 
recurrence.
In our study the only statistically signifficant risk 
factor preventing vulvar cancer recurrences was tumor 
involvement of middline (HR 0.46; p=0.02). This can be 
explained by more aggresive treatment of patients with 
middline involvement and thus better prognosis and less 
recurrences. Statistically there were no differences of 
vulvar cancer recurrences in patients with or without 
groin metastases (p=0.46), although this has been 
described in literature as a most signifficant risk factor 
predicting recurrent disease. In the study of Woelber et 
al. (2009) groin lymph node metastasis was the most 
important prognostic factor for disease-free and overall 
survival - patients with unilateral lymph node metastasis 
had a five-fold increased risk of recurrence compared to 
node-negative patients; in cases of bilateral lymph node 
involvement, this risk was 17 times higher.
Almost significant risk factors predicting vulvar 
cancer recurrence in our study was age over 70 years, 
tumor characteristics such as multilocular or unilocular 
and combined treatment of neoadjuvant radiotherapy 
following surgical treatment and adjuvant radiotherapy 
versus radiotherapy alone. There was a tendency for fewer 
vulvar cancer recurrences in patients over 70 years of age 
(HR 0.61; p=0.07). However, in the study of Woolderink 
et al. vulvar cancer recurrences more often were found in 
elderly patients (Woolderink et al., 2006).
Almost twice higher risk for vulvar cancer recurrence 
was observed in patients having multifoccal disease in 
contrast to patient with unilocular leasion, althought 
this factor didn’t reach statistical signifficance (HR 
1.91, p=0.08). This finding can be explained by tumor 
leasions that were left undiagnosed and thus led to tumor 
recurrence.  
The last risk factor found to be very close to reach 
statistical signifficance was neoadjuvant radiotherapy 
following sugery and adjuvant radiotherapy versus 
radiotherapy as an only treatment option (HR 1.66; 
p=0.06). Such finding can be explained by larger tumors 
and more widespread dissemination in patients receivind 
pre- and postoperative radiotherapy. Although patients 
who are receiving radiotherapy as an only treatment are 
not approprite for surgical treatment because of tumor 
spread, part of them are referred for radiotherapy because 
of co-morbidities and risk of wound dehiscence and not 
only because of wide tumor dissemination. 
In our study we didn’t evaluate a number of involved 
groin lymphnodes and neither involvement of pelvic 
lymphnodes, but there are some studies not showing any 
association between the number of metastatic lymph-
nodes and the risk of recurrence, while in other analyses 
involvement of two or more nodes, extracapsular spread 
and large size of the metastases were predictive of vulvar 
canccer recurrence (Origoni et al., 1992; Paladini et al., 
1994; Van et al., 1995; Lataifeh et al., 2004). 
In the literature as a risk factors predicting vulvar 
cancer recurrrence have been described also intracapsular 
lymph-node metastasis, lymphangio invasion and large 
primary tumours (Burger et al., 1995; Woelber et al., 2009; 
Oonk et al., 2010).
To get clear conclusions of vulvar cancer prognostic 
factors, large multicentric, prospective trial with uniform 
treatment approache is needed. In conclusions, patients 
having midline involvement of vulvar cancer has lower 
recurrence risk, probably because of receiving more 
aggressive treatment. There is a tendency for lower vulvar 
cancer recurrence risk for patients over 70 years of age 
and patients who are receiving radiotherapy as an only 
treatment without surgery, but tendency for higher risk 
of recurrence in patients with multifocal vulvar cancer.
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